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Vorapaxar is a selective antagonist of protease-activated receptor (PAR)-1 that potently blocks platelet activation by thrombin and has a long half-
life (>7 days). The impact of vorapaxar on bleeding related to invasive procedures is unknown.
methods: The TRA2°P-TIMI 50 trial was a randomized, double-blind, placebo controlled trial of vorapaxar 2.5mg daily in 26,449 patients with 
stable atherosclerosis followed for 2.5 yr (median). Study drug was to be continued before/after invasive procedures without interruption. Procedural 
bleeding was captured 1) by investigator classification as no bleeding, or bleeding that was less than, more than, or as expected, and 2) as GUSTO 
mod/severe bleeding adjudicated by a central CEC and identified as within 3 days of a procedure for this analysis.
results:  81% of invasive procedures were performed while continuing vorapaxar. Among non-CABG surgeries (n=5954), in pts allocated to 
vorapaxar, 1.4% were associated with more bleeding than expected compared with 1.1% with placebo (p=0.40). GUSTO mod/sev bleeding within 
3 days of the procedure in occurred 1.8% vs. 1.6% (p=0.56). Among non-surgical invasive procedures (n=5705), more than expected bleeding 
occurred in 0.6% vs. 0.3% (p=0.096) and GUSTO mod/sev in 1.8% vs. 1.3% with vorapaxar vs. placebo (p=0.20).
results:  In this large randomized placebo-controlled trial of vorapaxar, the rates of moderate or severe procedural bleeding were not significantly 
increased with vorapaxar.
 
